A Phase 3 interventional study of Lapatinib and Trastuzumab in Neoplasms, Breast, sponsored by Novartis Pharmaceuticals. Completed at 122 sites in 24 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-09-21.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
How we know · 9 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 114 studies testing lapatinib in Breast Neoplasms — none open to participants now, 3 under way, 1 of them phase 3. Lapatinib · Breast Neoplasms.
Among the 114 studies testing lapatinib in Breast Neoplasms, this one is the 8th largest by enrollment, is one of 15 that started in 2008, is one of 18 in phase 3, and was the 48th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →None of the 114 studies testing lapatinib in Breast Neoplasms is open now. The open studies under Breast Neoplasms, anywhere →
Lapatinib: first FDA approval 2007 (TYKERB), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
114 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 36 · Phase 2 70 · Phase 3 18
First in 2003; this study’s year is marked. 15 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 455 is above the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 35 across the 114 interventional studies. Of the 99 that completed or were terminated, 50 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
48 of 114 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,723 studies on the registry; 222 are open to participants now.
Of its 587 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
200 studies in Breast Neoplasms by Novartis: 17 open now, 31 under way, 4 of them phase 3. Of 160 finished, 74 (46%) have results posted.
Among the 200 studies in Breast Neoplasms by Novartis, this one is the 24th largest by enrollment of the 155 interventional ones that give a count, is one of 8 that started in 2008, is one of 45 in phase 3, and was the 51st registered.
Novartis’s Breast Neoplasms studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 114 studies testing lapatinib in Breast Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 200 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
This is a randomised, open label multicenter Phase III study comparing the efficacy of neoadjuvant lapatinib plus paclitaxel, versus trastuzumab plus paclitaxel, versus concomitant lapatinib and trastuzumab plus paclitaxel given as neoadjuvant treatment in HER2/ErbB2 over-expressing and/or amplified primary breast cancer.
Patients will be randomised to receive either: lapatinib 1500 mg daily, trastuzumab 4 mg/kg intravenous (IV) load followed by 2 mg/kg IV weekly, or lapatinib 1000 mg daily with trastuzumab 4 mg/kg IV load followed by 2 mg/kg IV weekly for a total of 6 weeks. After this biological window, patients on monotherapy arms will continue on the same targeted therapy plus weekly paclitaxel 80 mg/m\^2 for a further 12 weeks, up to definitive surgery. In the combination arm, patients will receive lapatinib 750 mg daily in combination with trastuzumab 2 mg/kg IV plus weekly paclitaxel 80mg/m\^2 IV for a further 12 weeks, up to definitive surgery. After surgery, patients will receive three courses of adjuvant chemotherapy with 5-Fluorouracil Epirubicin Cyclophosphamide (FEC) followed by the same targeted therapy as in the biological window of the neoadjuvant setting for a further 34 weeks (in the combination arm, lapatinib dose will be 1000 mg daily in combination with trastuzumab). The planned total duration of the anti-HER2 therapy one year.
Primary objective is to evaluate and compare the rate of pathological complete response (pCR) at the time of surgery in patients with HER2/ErbB2 overexpressing or amplified operable breast cancer randomised to lapatinib followed by lapatinib plus paclitaxel versus trastuzumab followed by trastuzumab plus paclitaxel versus lapatinib in combination with trastuzumab followed by lapatinib, trastuzumab plus paclitaxel.
This was a parallel group, three-arm, randomized, multicenter, open-label phase III study. The study compared the efficacy and tolerability of neoadjuvant lapatinib and paclitaxel, versus trastuzumab and paclitaxel, versus the combination of lapatinib with trastuzumab and paclitaxel given as neoadjuvant treatment in HER2/ErbB2 over-expressing and/or amplified primary breast cancer. Subjects were randomized to receive lapatinib, trastuzumab or lapatinib plus trastuzumab for a total of 6 weeks. After this biological window, subjects continued on the same targeted therapy plus weekly paclitaxel for a further 12 weeks, until definitive surgery (total neoadjuvant therapy duration of 18 weeks). Paclitaxel could be initiated at Week 4 if there is evidence of progressive disease (PD) at that time. Within 6 weeks after surgery, subjects received 3 cycles of adjuvant 5-flourouracil, epirubicin and cyclophosphamide (FEC) followed by the same targeted therapy as in the biological window of the neoadjuvant phase for a further 34 weeks (to complete 52 weeks of anti-HER2 therapy).
After completing 52 weeks of (neo-)/adjuvant anti-HER2 therapy, subjects were scheduled to attend post-treatment follow-up every 3 months during the first year (months 12, 15, 18, 21, and 24), every 6months in Years 3 to 5 inclusive, and annually thereafter up to Year 10. Each subject was to be followed for 10 Years. All subjects were to be followed for EFS and OS up to 10 years from last subject randomized.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1500 mg lapatinib for 6 weeks followed by lapatinib plus weekly paclitaxel for an additional 12 weeks. After definitive surgery, 3 cycles of adjuvant FEC followed by 34 weeks of adjuvant lapatinib.
Drug: Lapatinib · Drug: Paclitaxel
4 mg/kg IV loading dose followed by 2 mg/kg IV weekly trastuzumab for 6 weeks followed by 2 mg/kg trastuzumab plus weekly paclitaxel for an additional 12 weeks. After definitive surgery, 3 cycles of adjuvant FEC followed by 34 weeks of adjuvant trastuzumab (8 mg/kg loading dose followed by 6 mg/kg every 3 weeks).
Biological: Trastuzumab · Drug: Paclitaxel
1000 mg lapatinib plus 4 mg/kg IV loading dose followed by 2 mg/kg IV weekly trastuzumab for 6 weeks, followed by 750 mg lapatinib plus 2 mg/kg IV weekly trastuzumab plus weekly paclitaxel for an additional 12 weeks. After definitive surgery, 3 cycles of adjuvant FEC followed by 34 weeks of adjuvant lapatinib (1000 mg) in combination with trastuzumab (8 mg/kg loading dose followed by 6 mg/kg every 3 weeks).
Drug: Lapatinib · Biological: Trastuzumab · Drug: Paclitaxel
Small molecule receptor tyrosine kinase inhibitor
Therapeutic Monoclonal Antibody
antimicrotubule agent
Number of Participants With Pathological Complete Response (pCR) at the Time of Surgery
Pathological complete response is defined as no invasive cancer in the breast or only non-invasive in situ cancer in the breast specimen. Surgical breast and axillary node resection specimens were evaluated for pathologic tumor response according to National Surgical Adjuvant Breast and Bowel Project (NSABP) guidelines, which do not take into account the histological nodal status.
Time frame: Weeks 20 to 22
Number of Participants With Overall Response at Week 6
The number of participants with overall response (complete response and/or partial response) was evaluated using World Health Organization (WHO) criteria by clinical examination and by mammography and breast echography with bi-dimensional measurements at Week 6. As per WHO criteria: complete response is defined as the disappearance of all lesions; partial response is defined as a greater than 50% decrease in the sum of products of the greatest length and width of the largest lesion; progressive disease is defined as a greater than 25% increase in the sum of products of all measurable lesions.
Time frame: Week 6
Overall Response at the Time of Surgery
The number of participants with overall response (complete response and/or partial response) was evaluated using WHO criteria by clinical examination and mammography and breast echography with bi-dimensional measurements at the time of surgery (Weeks 20 to 22). As per WHO criteria: complete response is defined as the disappearance of all lesions; partial response is defined as a greater than 50% decrease in the sum of products of the greatest length and width of the largest lesion; progressive disease is defined as a greater than 25% increase in the sum of products of all measurable lesions.
Time frame: Time of surgery (Weeks 20 to 22)
Number of Participants With Negative Lymph Nodes at the Time of Surgery
Participants were assessed for node-negative lymph nodes at the time of surgery. As per the pathological TNM (Tumor, Node, Metastases) classification (pTNM) of malignant tumors: pN, absence or presence and extent of regional lymph node metastasis. Node-negative (pN0) participants had no regional lymph node metastasis. Although not assessed in this measure, pT is the extent of primary tumor, and pM is the absence or presence of distant metastasis.
Time frame: Time of surgery (Weeks 20 to 22)
Number of Participants With Actual Indicated Surgery
Participants were assessed for the type of surgery they underwent for breast cancer. Non-conservative surgery is defined as a radical or modified radical mastectomy. Conservative surgery is comprised of a lumpectomy, a quadrantectomy/segmentectomy, or a partial mastectomy. Participants who were not assessed as being candidates for non-conservative or conservative surgery were classified as non-operable.
Time frame: At surgery (Weeks 20 to 22)
Mean Change From Baseline in Tumor Size at Week 6 and at Surgery
Mean change from baseline in tumor in tumor size. Change from baseline in tumor size was defined as tumor size at Week 6/ surgery (Weeks 20 to 22) minus tumor size at baseline. The difference in treatment arms was estimated for Lapatinib 1500 mg versus Trastuzumab 2 mg/kg and for Lapatinib 1000/750 mg + Trastuzumab 2 mg/kg versus Trastuzumab 2 mg/kg.
Time frame: Week 6 and surgery (Weeks 20 to 22)
Number of Participants Starting Paclitaxel Before Completing 6 Weeks of Treatment With Either Lapatinib or Trastuzumab
Participants with progressive disease at 4 week assessment that were permitted to commence treatment with paclitaxel.
Time frame: Week 6
Event-free Survival (EFS) - Median Clinical Follow-up
Event free survival (EFS) is defined as the time from randomization to first EFS event. For subjects who had breast cancer surgery, EFS events were post-surgery breast cancer relapse, second primary malignancy or death without recurrence. For subjects who did not have breast cancer surgery, EFS events were death during clinical follow-up or non-completion of any neoadjuvant investigational product due to disease progression.
Time frame: From randomization up to approximately year 10
Event-free Survival (EFS) - Events and Censoring
Event free survival (EFS) is defined as the time from randomization to first EFS event. For subjects who had breast cancer surgery, EFS events were post-surgery breast cancer relapse, second primary malignancy or death without recurrence. For subjects who did not have breast cancer surgery, EFS events were death during clinical follow-up or non-completion of any neoadjuvant investigational product due to disease progression.
Time frame: From randomization up to approximately year 10
Overall Survival (OS) - Median Survival Follow-up
Overall survival is defined as the period from randomization until death (from any cause). OS was assessed annually for up to 10 years after the randomization of the last participant into the study.
Time frame: From randomization up to approximately year 10
Overall Survival (OS) - Deaths and Censoring
Overall survival is defined as the period from randomization until death (from any cause). OS was assessed annually for up to 10 years after the randomization of the last participant into the study.
Time frame: From randomization up to approximately year 10
Assess Associations Between Locoregional Pathological Complete Response (pCR) and Event-free Survival (EFS) - Median Clinical Follow-up (EFS Landmark Population)
The landmark date is 30 weeks after a subject's randomization. Subjects with missing pCR status were not included in the landmark analysis. Clinical follow-up is the period during which the patient is monitored such that all recurrence or second primary malignancy (SPM) or contralateral breast cancer (CBC) events would be reported. Patients are considered in clinical follow-up from randomisation until one of the following occurs: lost to follow-up, withdrawal of consent, end of follow-up due to completion of year 10 visit, termination of study follow-up, or death.
Time frame: up to year 10
Assess Associations Between Locoregional Pathological Complete Response (pCR) and Event-free Survival (EFS) - Number of Participants With EFS Events (EFS Landmark Population)
The landmark date is 30 weeks after a subject's randomization. Subjects with missing pCR status were not included in the landmark analysis. For patients who had breast cancer surgery, EFS events are post-surgery breast cancer relapse, second primary malignancy or death without recurrence. For patients who do not undergo breast cancer surgery, EFS events are death during clinical follow-up or non-completion of any neo-adjuvant investigational product due to disease progression or second primary malignancy or contralateral breast cancer.
Time frame: up to year 10
Assess Associations Between Locoregional Pathological Complete Response (pCR) and and Overall Survival (OS) - Median Clinical Follow-up (OS Landmark Population)
The landmark date is 30 weeks after a subject's randomization. Subjects with missing pCR status were not included in the landmark analysis. Patients are considered in survival follow-up from randomisation until one of the following occurs: lost to follow-up, withdrawal of consent, end of follow-up due to completion of year 10 visit, termination of study follow-up, or death. For subjects with no death recorded in the database, time to death is censored.
Time frame: up to year 10
Assess Associations Between Locoregional Pathological Complete Response (pCR) and and Overall Survival (OS) - Number of Participants Who Died (OS Landmark Population)
The landmark date is 30 weeks after a subject's randomization. Subjects with missing pCR status were not included in the landmark analysis. Includes deaths due to any cause.
Time frame: up to year 10
To Assess Safety Via a Comparison of the Three Treatment Arms - to Measure On-treatment Primary Cardiac Endpoints
Time frame: Adverse events were collected from first dose of study treatment until end of study treatment plus 30 days post treatment, up to maximum duration of 31 weeks.
Metabolic Response Rate Determined by Positron Emission Tomography/Computed Tomography (PET/CT)
Metabolic Response Rate determined by Positron Emission Tomography/Computed Tomography (PET/CT)
Time frame: Week 2 and Week 6
Percentage of Participants With the Indicated Biomarker Expression - PIK3CA.
Biomarker levels of phosphatidylinositol 3-kinase (PI3K) catalytic subunit (PIK3CA) were assessed in participants at baseline.
Time frame: Baseline
Percentage of Participants With the Indicated Biomarker Expression - PTEN.
Biomarker levels of phosphate and tensin homolog deleted from chromosome 10 (PTEN) were assessed in participants at baseline.
Time frame: Baseline
Ratio (95% CI) of Geometric Means in p95HER2 Expression in HR Positive Patients With pCR vs no pCR
Ratio (95% CI) of geometric means in p95 human epidermal growth factor receptor (p95HER2) expression in hormone-receptor (HR) positive patients with pathological complete response (pCR) vs no pCR
Time frame: Baseline
Percentage of Participants With Circulating Tumor Cells (CTC) in the Bloodstream
Circulating tumor cells (CTCs) are cells that have detached from a primary tumor and circulate in the bloodstream. In the adjuvant phase, after surgery all participants received 3 courses of adjuvant 5-fluorouracil, epirubicin and cyclophosphamide, followed by lapatinib 1500 mg or trastuzumab 2 mg/kg or lapatinib 1000/750 mg plus trastuzumab 2 mg/kg given prior to surgery in the neoadjuvant setting for an additional 34 weeks.
Time frame: Measurement performed at one or more of the time points: baseline, week 2 or week 18
| Milestone | Lapatinib 1000/750 mg + Trastuzumab 2 mg/kg | Lapatinib 1500 mg | Trastuzumab 2 mg/kg |
|---|---|---|---|
| Started | 152 | 154 | 149 |
| Completed | 73 | 58 | 61 |
| Not completed | 79 | 96 | 88 |
| Withdrew: Randomized but did not receive treatment | 3 | 3 | 1 |
| Withdrew: Lost to follow-up | 22 | 26 | 18 |
| Withdrew: Withdrew completely | 23 | 33 | 34 |
| Withdrew: Died during clinical follow-up | 25 | 29 | 32 |
| Withdrew: Not dead but were last followed-up prior to 9 years + 6 months after randomization | 4 | 2 | 2 |
| Withdrew: Died after clinical follow-up ended | 1 | 2 | 0 |
| Withdrew: Withdrew (survival only) - alive at end of survival follow-up | 1 | 1 | 1 |
Pathological complete response is defined as no invasive cancer in the breast or only non-invasive in situ cancer in the breast specimen. Surgical breast and axillary node resection specimens were evaluated for pathologic tumor response according to National Surgical Adjuvant Breast and Bowel Project (NSABP) guidelines, which do not take into account the histological nodal status.
| participants | Lapatinib 1500 mg | Trastuzumab 2 mg/kg | Lapatinib 1000/750 mg + Trastuzumab 2 mg/kg |
|---|---|---|---|
| Number of Participants With Pathological Complete Response (pCR) at the Time of Surgery | 38 | 44 | 78 |
The number of participants with overall response (complete response and/or partial response) was evaluated using World Health Organization (WHO) criteria by clinical examination and by mammography and breast echography with bi-dimensional measurements at Week 6. As per WHO criteria: complete response is defined as the disappearance of all lesions; partial response is defined as a greater than 50% decrease in the sum of products of the greatest length and width of the largest lesion; progressive disease is defined as a greater than 25% increase in the sum of products of all measurable lesions.
| participants | Lapatinib 1500 mg | Trastuzumab 2 mg/kg | Lapatinib 1000/750 mg + Trastuzumab 2 mg/kg |
|---|---|---|---|
| Overall Response | 81 | 45 | 102 |
| No Change | 57 | 81 | 33 |
| Progressive Disease | 5 | 11 | 2 |
| Not Evaluated | 7 | 9 | 12 |
| Missing Data | 4 | 3 | 3 |
The number of participants with overall response (complete response and/or partial response) was evaluated using WHO criteria by clinical examination and mammography and breast echography with bi-dimensional measurements at the time of surgery (Weeks 20 to 22). As per WHO criteria: complete response is defined as the disappearance of all lesions; partial response is defined as a greater than 50% decrease in the sum of products of the greatest length and width of the largest lesion; progressive disease is defined as a greater than 25% increase in the sum of products of all measurable lesions.
| participants | Lapatinib 1500 mg | Trastuzumab 2 mg/kg | Lapatinib 1000/750 mg + Trastuzumab 2 mg/kg |
|---|---|---|---|
| Overall Response | 114 | 105 | 122 |
| No Change | 8 | 16 | 7 |
| Progressive Disease | 0 | 2 | 1 |
| Not Evaluated | 19 | 20 | 14 |
| Missing Data | 13 | 6 | 8 |
Participants were assessed for node-negative lymph nodes at the time of surgery. As per the pathological TNM (Tumor, Node, Metastases) classification (pTNM) of malignant tumors: pN, absence or presence and extent of regional lymph node metastasis. Node-negative (pN0) participants had no regional lymph node metastasis. Although not assessed in this measure, pT is the extent of primary tumor, and pM is the absence or presence of distant metastasis.
| participants | Lapatinib 1500 mg | Trastuzumab 2 mg/kg | Lapatinib 1000/750 mg + Trastuzumab 2 mg/kg |
|---|---|---|---|
| Number of Participants With Negative Lymph Nodes at the Time of Surgery | 72 | 82 | 100 |
Participants were assessed for the type of surgery they underwent for breast cancer. Non-conservative surgery is defined as a radical or modified radical mastectomy. Conservative surgery is comprised of a lumpectomy, a quadrantectomy/segmentectomy, or a partial mastectomy. Participants who were not assessed as being candidates for non-conservative or conservative surgery were classified as non-operable.
| participants | Lapatinib 1500 mg | Trastuzumab 2 mg/kg | Lapatinib 1000/750 mg + Trastuzumab 2 mg/kg |
|---|---|---|---|
| Conservative | 66 | 58 | 63 |
| Non-conservative | 77 | 85 | 80 |
| Non-operable | 11 | 6 | 9 |
Mean change from baseline in tumor in tumor size. Change from baseline in tumor size was defined as tumor size at Week 6/ surgery (Weeks 20 to 22) minus tumor size at baseline. The difference in treatment arms was estimated for Lapatinib 1500 mg versus Trastuzumab 2 mg/kg and for Lapatinib 1000/750 mg + Trastuzumab 2 mg/kg versus Trastuzumab 2 mg/kg.
| millimeters | Lapatinib 1500 mg | Trastuzumab 2 mg/kg | Lapatinib 1000/750 mg + Trastuzumab 2 mg/kg |
|---|---|---|---|
| Week 6 | -20.45 ± 18.43 | -13.42 ± 16.44 | -25.77 ± 19.91 |
| Surgery (Weeks 20 to 22) | -41.01 ± 23.81 | -35.47 ± 22.95 | -43.59 ± 26.88 |
Participants with progressive disease at 4 week assessment that were permitted to commence treatment with paclitaxel.
| participants | Lapatinib 1500 mg | Trastuzumab 2 mg/kg | Lapatinib 1000/750 mg + Trastuzumab 2 mg/kg |
|---|---|---|---|
| Number of Participants Starting Paclitaxel Before Completing 6 Weeks of Treatment With Either Lapatinib or Trastuzumab | 8 | 12 | 6 |
Event free survival (EFS) is defined as the time from randomization to first EFS event. For subjects who had breast cancer surgery, EFS events were post-surgery breast cancer relapse, second primary malignancy or death without recurrence. For subjects who did not have breast cancer surgery, EFS events were death during clinical follow-up or non-completion of any neoadjuvant investigational product due to disease progression.
| years | Lapatinib 1000/750 mg + Trastuzumab 2 mg/kg | Lapatinib 1500 mg | Trastuzumab 2 mg/kg |
|---|---|---|---|
| Event-free Survival (EFS) - Median Clinical Follow-up | 9.69 (9.55 to 9.73) | 9.60 (8.21 to 9.69) | 9.66 (9.50 to 9.72) |
Event free survival (EFS) is defined as the time from randomization to first EFS event. For subjects who had breast cancer surgery, EFS events were post-surgery breast cancer relapse, second primary malignancy or death without recurrence. For subjects who did not have breast cancer surgery, EFS events were death during clinical follow-up or non-completion of any neoadjuvant investigational product due to disease progression.
| Number of Participants | Lapatinib 1000/750 mg + Trastuzumab 2 mg/kg | Lapatinib 1500 mg | Trastuzumab 2 mg/kg |
|---|---|---|---|
| Number of subjects with EFS events | 43 | 47 | 47 |
| Number of subjects censored - total | 109 | 107 | 102 |
| Number of subjects censored - Clinical follow-up ongoing | 0 | 0 | 0 |
| Number of subjects censored - Clinical follow-up ended - total | 103 | 105 | 99 |
| Number of subjects censored -Clinical follow-up ended - Completed study follow-up | 61 | 49 | 58 |
| Number of subjects censored - Clinical follow-up ended - Lost to follow-up | 17 | 20 | 10 |
| Number of subjects censored - Clinical follow-up ended - Withdrew (but consent for survival f/u) | 3 | 6 | 4 |
| Number of subjects censored - Clinical follow-up ended - Withdrew | 22 | 30 | 27 |
| Number of subjects censored - Other | 6 | 2 | 3 |
Overall survival is defined as the period from randomization until death (from any cause). OS was assessed annually for up to 10 years after the randomization of the last participant into the study.
| years | Lapatinib 1000/750 mg + Trastuzumab 2 mg/kg | Lapatinib 1500 mg | Trastuzumab 2 mg/kg |
|---|---|---|---|
| Overall Survival (OS) - Median Survival Follow-up | 9.70 (9.60 to 9.76) | 9.62 (8.86 to 9.67) | 9.64 (9.35 to 9.71) |
Overall survival is defined as the period from randomization until death (from any cause). OS was assessed annually for up to 10 years after the randomization of the last participant into the study.
| Number of Participants | Lapatinib 1000/750 mg + Trastuzumab 2 mg/kg | Lapatinib 1500 mg | Trastuzumab 2 mg/kg |
|---|---|---|---|
| Number of deaths due to any cause | 26 | 31 | 32 |
| Number of subjects censored - total | 126 | 123 | 117 |
| Number of subjects censored - Survival follow-up ongoing | 0 | 0 | 0 |
| Number of subjects censored - Survival follow-up ended - total | 120 | 121 | 114 |
| Number of subjects censored -Survival follow-up ended - Completed study follow-up | 74 | 59 | 62 |
| Number of subjects censored - Survival follow-up ended - Lost to follow-up | 22 | 27 | 18 |
| Number of subjects censored - Survival follow-up ended - Withdrew | 24 | 35 | 34 |
| Number of subjects censored - Other | 6 | 2 | 3 |
The landmark date is 30 weeks after a subject's randomization. Subjects with missing pCR status were not included in the landmark analysis. Clinical follow-up is the period during which the patient is monitored such that all recurrence or second primary malignancy (SPM) or contralateral breast cancer (CBC) events would be reported. Patients are considered in clinical follow-up from randomisation until one of the following occurs: lost to follow-up, withdrawal of consent, end of follow-up due to completion of year 10 visit, termination of study follow-up, or death.
| years | Pathological Complete Response (pCR) | No Pathological Complete Response (pCR) | Overall |
|---|---|---|---|
| Median clinical follow-up - all subjects in the EFS landmark analysis | 9.05 (8.86 to 9.14) | 9.11 (9.05 to 9.14) | 9.09 (9.03 to 9.13) |
| Median clinical follow-up- EFS landmark analysis - lapatinib + trastuzumab arm (n=67,71,138) | 9.13 (8.97 to 9.23) | 9.10 (7.24 to 9.15) | 9.12 (8.97 to 9.15) |
| Median clinical follow-up - subjects in the EFS landmark analysis - lapatinib arm (n=30,104,134) | 8.08 (6.08 to 9.12) | 9.09 (8.52 to 9.19) | 9.05 (8.23 to 9.12) |
| Median clinical follow-up - subjects in the EFS landmark analysis - trastuzumab arm (n=39,99,138) | 8.98 (8.38 to 9.21) | 9.12 (9.03 to 9.25) | 9.11 (8.96 to 9.17) |
The landmark date is 30 weeks after a subject's randomization. Subjects with missing pCR status were not included in the landmark analysis. For patients who had breast cancer surgery, EFS events are post-surgery breast cancer relapse, second primary malignancy or death without recurrence. For patients who do not undergo breast cancer surgery, EFS events are death during clinical follow-up or non-completion of any neo-adjuvant investigational product due to disease progression or second primary malignancy or contralateral breast cancer.
| Number of participants | Pathological Complete Response (pCR) | No Pathological Complete Response (pCR) | Overall |
|---|---|---|---|
| All subjects in the EFS landmark analysis with EFS events | 29 | 98 | 127 |
| Subjects in the EFS landmark analysis - lapatinib + trastuzumab arm with EFS events (n=67,71,138) | 11 | 28 | 39 |
| Subjects in the EFS landmark analysis in the lapatinib arm with EFS events (n=30,104,134) | 7 | 36 | 43 |
| Subjects in the EFS landmark analysis in the trastuzumab arm with EFS events (n=39,99,138) | 11 | 34 | 45 |
The landmark date is 30 weeks after a subject's randomization. Subjects with missing pCR status were not included in the landmark analysis. Patients are considered in survival follow-up from randomisation until one of the following occurs: lost to follow-up, withdrawal of consent, end of follow-up due to completion of year 10 visit, termination of study follow-up, or death. For subjects with no death recorded in the database, time to death is censored.
| years | Pathological Complete Response (pCR) | No Pathological Complete Response (pCR) | Overall |
|---|---|---|---|
| Median survival follow-up - All subjects in the OS landmark analysis | 9.10 (8.97 to 9.18) | 9.09 (9.03 to 9.12) | 9.09 (9.04 to 9.13) |
| Median survival follow-up - OS landmark analysis in the lapatinib + trastuzumab arm (n=67,72,139) | 9.14 (9.05 to 9.24) | 9.09 (7.95 to 9.15) | 9.12 (9.05 to 9.16) |
| Median survival follow-up - OS landmark analysis in the lapatinib (n=30,109,139) | 8.31 (7.24 to 9.15) | 9.08 (8.95 to 9.14) | 9.07 (8.50 to 9.12) |
| Median survival follow-up - OS landmark analysis in the trastuzumab arm (n=40,102,142) | 8.98 (8.02 to 9.21) | 9.09 (8.51 to 9.15) | 9.07 (8.86 to 9.14) |
The landmark date is 30 weeks after a subject's randomization. Subjects with missing pCR status were not included in the landmark analysis. Includes deaths due to any cause.
| Number of Participants | Pathological Complete Response (pCR) | No Pathological Complete Response (pCR) | Overall |
|---|---|---|---|
| All participants in the OS landmark analysis who died | 15 | 70 | 85 |
| Participants in the OS landmark analysis in the lapatinib + trastuzumab arm who died (n=67,72,139) | 5 | 19 | 24 |
| Participants in the OS landmark analysis in the lapatinib arm who died (n=30,109,139) | 4 | 26 | 30 |
| Participants in the OS landmark analysis in the trastuzumab arm who died (n=40,102,142) | 6 | 25 | 31 |
| Participants | Lapatinib 1000/750 mg + Trastuzumab 2 mg/kg | Lapatinib 1500 mg | Trastuzumab 2 mg/kg |
|---|---|---|---|
| To Assess Safety Via a Comparison of the Three Treatment Arms - to Measure On-treatment Primary Cardiac Endpoints | 2 (0.16 to 4.76) | 0 (0.00 to 2.41) | 1 (0.02 to 3.71) |
Metabolic Response Rate determined by Positron Emission Tomography/Computed Tomography (PET/CT)
| Percentage of participants | Lapatinib 1500 mg | Trastuzumab 2 mg/kg | Lapatinib 1000/750 mg + Trastuzumab 2 mg/kg |
|---|---|---|---|
| Metabolic Response Rate (%) Determined by PET/CT at week 2 | 66.7 | 56.5 | 95.0 |
| Metabolic Response Rate (%) Determined by PET/CT at week 6 | 60.9 | 43.5 | 78.9 |
Biomarker levels of phosphatidylinositol 3-kinase (PI3K) catalytic subunit (PIK3CA) were assessed in participants at baseline.
| Percentage of participants | Lapatinib 1500 mg | Trastuzumab 2 mg/kg | Lapatinib 1000/750 mg + Trastuzumab 2 mg/kg |
|---|---|---|---|
| Percentage of Participants With the Indicated Biomarker Expression - PIK3CA. | 23 | 19 | 25 |
Biomarker levels of phosphate and tensin homolog deleted from chromosome 10 (PTEN) were assessed in participants at baseline.
| Percentage of participants | Lapatinib 1500 mg | Trastuzumab 2 mg/kg | Lapatinib 1000/750 mg + Trastuzumab 2 mg/kg |
|---|---|---|---|
| Biomarker: PTEN by Cell Signalling Technology - PTEN Normal (%) | 74 | 70 | 75 |
| Biomarker: PTEN by Cell Signalling Technology - PTEN Loss (%) | 26 | 30 | 25 |
Ratio (95% CI) of geometric means in p95 human epidermal growth factor receptor (p95HER2) expression in hormone-receptor (HR) positive patients with pathological complete response (pCR) vs no pCR
| Ratio | Lapatinib 1500 mg | Trastuzumab 2 mg/kg | Lapatinib 1000/750 mg + Trastuzumab 2 mg/kg |
|---|---|---|---|
| Ratio (95% CI) of Geometric Means in p95HER2 Expression in HR Positive Patients With pCR vs no pCR | 1.0 (0.50 to 1.87) | 1.6 (1.0 to 2.71) | 2.1 (1.2 to 3.7) |
Circulating tumor cells (CTCs) are cells that have detached from a primary tumor and circulate in the bloodstream. In the adjuvant phase, after surgery all participants received 3 courses of adjuvant 5-fluorouracil, epirubicin and cyclophosphamide, followed by lapatinib 1500 mg or trastuzumab 2 mg/kg or lapatinib 1000/750 mg plus trastuzumab 2 mg/kg given prior to surgery in the neoadjuvant setting for an additional 34 weeks.
| Percentage of Participants | Lapatinib 1500 mg | Trastuzumab 2 mg/kg | Lapatinib 1000/750 mg + Trastuzumab 2 mg/kg |
|---|---|---|---|
| Percentage of Participants With Circulating Tumor Cells (CTC) in the Bloodstream | 21 | 17 | 25 |
On treatment deaths were collected from FPFT up to 30 days after study drug discontinuation, which was approximately 31 weeks. Deaths post treatment survival follow up were collected after the on treatment period, up to 10 years.
| Participants | Lapatinib 1500 mg | Trastuzumab 2 mg/kg | Lapatinib 1000/750 mg + Trastuzumab 2 mg/kg |
|---|---|---|---|
| Total Deaths | 31 | 32 | 26 |
| On-Treatment Deaths (n=151,148,149) | 2 | 0 | 1 |
Collected over Adverse events were collected from first dose of study treatment until end of study treatment plus 30 days post treatment, up to maximum duration of 31 weeks.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lapatinib 1000/750 mg + Trastuzumab 2 mg/kg | 1/149 (0.7%) | 61/149 (40.9%) | 147/149 (98.7%) |
| Lapatinib 1500 mg | 2/151 (1.3%) | 58/151 (38.4%) | 148/151 (98%) |
| Trastuzumab 2 mg/kg | 0/148 (0%) | 36/148 (24.3%) | 141/148 (95.3%) |
| Event | Lapatinib 1000/750 mg + Trastuzumab 2 mg/kg | Lapatinib 1500 mg | Trastuzumab 2 mg/kg |
|---|---|---|---|
| HYPERTRANSAMINASAEMIAHepatobiliary disorders | 15/149 | 23/151 | 3/148 |
| NEUTROPENIABlood and lymphatic system disorders | 14/149 | 13/151 | 16/148 |
| DIARRHOEAGastrointestinal disorders | 9/149 | 9/151 | 0/148 |
| FEBRILE NEUTROPENIABlood and lymphatic system disorders | 3/149 | 2/151 | 8/148 |
| PYREXIAGeneral disorders | 5/149 | 2/151 | 2/148 |
| HYPERBILIRUBINAEMIAHepatobiliary disorders | 4/149 | 4/151 | 0/148 |
| CARDIAC FAILURE CONGESTIVECardiac disorders | 3/149 | 0/151 | 1/148 |
| VOMITINGGastrointestinal disorders | 3/149 | 1/151 | 2/148 |
| URINARY TRACT INFECTIONInfections and infestations | 0/149 | 3/151 | 0/148 |
| CELLULITISInfections and infestations | 2/149 | 1/151 | 2/148 |
| Event | Lapatinib 1000/750 mg + Trastuzumab 2 mg/kg | Lapatinib 1500 mg | Trastuzumab 2 mg/kg |
|---|---|---|---|
| DIARRHOEAGastrointestinal disorders | 128/149 | 123/151 | 52/148 |
| ALOPECIASkin and subcutaneous tissue disorders | 95/149 | 90/151 | 96/148 |
| NAUSEAGastrointestinal disorders | 75/149 | 81/151 | 76/148 |
| RASHSkin and subcutaneous tissue disorders | 67/149 | 68/151 | 28/148 |
| VOMITINGGastrointestinal disorders | 54/149 | 57/151 | 38/148 |
| HYPERTRANSAMINASAEMIAHepatobiliary disorders | 55/149 | 55/151 | 39/148 |
| FATIGUEGeneral disorders | 52/149 | 45/151 | 38/148 |
| NEUTROPENIABlood and lymphatic system disorders | 47/149 | 51/151 | 37/148 |
| ASTHENIAGeneral disorders | 39/149 | 47/151 | 35/148 |
| DECREASED APPETITEMetabolism and nutrition disorders | 35/149 | 39/151 | 17/148 |
| Age, Continuous(Years) | Lapatinib 1500 mg | Trastuzumab 2 mg/kg | Lapatinib 1000/750 mg + Trastuzumab 2 mg/kg | Total |
|---|---|---|---|---|
| Median | 50.0 (28 to 79) | 49.0 (23 to 77) | 50.0 (25 to 80) | 50.0 (23 to 80) |
| Sex: Female, Male(Participants) | Lapatinib 1500 mg | Trastuzumab 2 mg/kg | Lapatinib 1000/750 mg + Trastuzumab 2 mg/kg | Total |
|---|---|---|---|---|
| Female | 154 | 149 | 152 | 455 |
| Male | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Lapatinib 1500 mg | Trastuzumab 2 mg/kg | Lapatinib 1000/750 mg + Trastuzumab 2 mg/kg | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 13 | 14 | 15 | 42 |
| Asian - Central/South | 7 | 5 | 5 | 17 |
| Asian - East | 30 | 28 | 31 | 89 |
| Asian - South East | 0 | 0 | 2 | 2 |
| Black or African American/African Heritage | 0 | 4 | 4 | 8 |
| White - Arabic/North African Heritage | 6 | 5 | 3 | 14 |
| White - Caucasian European Heritage | 97 | 93 | 92 | 282 |
| Missing | 1 | 0 | 0 | 1 |
| Number of participants with tumor cells of the indicated histologic grade(Participants) | Lapatinib 1500 mg | Trastuzumab 2 mg/kg | Lapatinib 1000/750 mg + Trastuzumab 2 mg/kg | Total |
|---|---|---|---|---|
| Well differentiated | 2 | 5 | 5 | 12 |
| Moderately differentiated | 56 | 53 | 63 | 172 |
| Poorly differentiated | 73 | 68 | 64 | 205 |
| Differentiation cannot be assessed | 22 | 23 | 20 | 65 |
| Missing | 1 | 0 | 0 | 1 |
| Number of participants with lymph nodes (LNs) of the indicated clinical N stage(Participants) | Lapatinib 1500 mg | Trastuzumab 2 mg/kg | Lapatinib 1000/750 mg + Trastuzumab 2 mg/kg | Total |
|---|---|---|---|---|
| N0 | 34 | 41 | 48 | 123 |
| N1 | 95 | 85 | 80 | 260 |
| N2 (including N2a and N2b) | 19 | 13 | 15 | 47 |
| N3 (including N3a, N3b, and N3c) | 6 | 7 | 6 | 19 |
| Nx | 0 | 3 | 3 | 6 |
| Number of participants with the indicated IHC results(Participants) | Lapatinib 1500 mg | Trastuzumab 2 mg/kg | Lapatinib 1000/750 mg + Trastuzumab 2 mg/kg | Total |
|---|---|---|---|---|
| Not applicable | 60 | 53 | 61 | 174 |
| Equivocal: Score of 2+ | 9 | 5 | 8 | 22 |
| Positive: Score of 3+ | 81 | 89 | 76 | 246 |
| Negative: Score of 0-1+ | 0 | 1 | 3 | 4 |
| Non interpretable | 4 | 1 | 4 | 9 |
| Number of participants with the indicated FISH results(Participants) | Lapatinib 1500 mg | Trastuzumab 2 mg/kg | Lapatinib 1000/750 mg + Trastuzumab 2 mg/kg | Total |
|---|---|---|---|---|
| Not applicable | 38 | 42 | 41 | 121 |
| Amplified | 115 | 105 | 109 | 329 |
| Not amplified | 1 | 2 | 1 | 4 |
| Not interpretable | 0 | 0 | 1 | 1 |
Showing the first 100 of 122 sites across 24 countries. Choose a country and city above to see the rest.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.
Data sharing details ↗ · www.clinicalstudydatarequest.com
Ran from Jan 2008 to primary completion in May 2010, 28 months.
Results were first posted in Oct 2011, 1 year 4 months after primary completion.
Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 28 months is below that.
Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Lapatinib · Trastuzumab